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Abstract 
 
An ideal tracheal scaffold must withstand luminal collapse yet be flexible, have a sufficient degree of porosity to 
permit vascular and cellular ingrowth, but also be airtight and must facilitate growth of functional airway 
epithelium to avoid infection and aid in mucocilliary clearance. Finally, the scaffold must also be biocompatible 
to avoid implant rejection. Over the last 40 years, efforts to design and manufacture the airway have been 
undertaken worldwide but success has been limited and far apart. As a result, tracheal resection with primary 
repair remains the Gold Standard of care for patients presenting with airway disorders and malignancies. 
However, the maximum resectable length of the trachea is restricted to 30% of the total length in children or 
50% in adults. Attempts to provide autologous grafts for human application have also been disappointing for a 
host of different reasons, including lack of implant integration, insufficient donor organs and poor mechanical 
strength resulting in an unmet clinical need. The two main approaches researchers have taken to address this 
issue have been the development of synthetic scaffolds and the use of decellularised organs. To date, a number 
of different decellularisation techniques and a variety of materials, including polyglycolic acid  (PGA) and 
nanocomposite polymers have been explored.  The findings thus far have shown great promise, however there 
remain a significant number of caveats accompanying each approach. That being said, the possibilities presented 
by these two approaches could be combined to produce a highly successful, clinically viable hybrid scaffold. 
This article aims to highlight advances in airway tissue engineering and provide an overview of areas to explore 
and utilise in accomplishing the aim of a developing an ideal tracheal prosthesis.  
 
1. Introduction 
Disorders of the trachea can lead to serious health complications, significantly reducing the quality of life for 
patients. These vary but include tracheal carcinoma, tracheo-esophageal fistulae, stenosis, tracheobronchial 
malacia and injury, or the ingestion of harmful substances. Existing treatment options are limited; currently the 
Gold Standard treatment is tracheal resection with a primary reconstruction to restore continuity. Other therapies 
include aortopexy, tracheal stenting, or slide tracheoplasty, but these have mixed levels of success. To date, 
there is no clinically viable option available for patients with long segmental airway disorders. In adults, only 
half of the tracheal length, approximately 6cm, can be successfully treated by resection, and even less in 
children where only one third of the length of the trachea can be reconstructed
1,2
.  
 
Alternative options for trachea replacement are being developed, including autografts, allografts, and 
prosthetics, or a combination of these; but they have limitations including inflammation, infection, improper 
sizing, and a failure to effectively mimic the physiological properties of the original tissue
1–8
. With the 
advancements made in tissue engineering (TE) in the last 40 years
4,9
, researchers are focusing on utilising a 
tracheal scaffold made from a suitable synthetic polymer or a cadaveric allotransplant. To properly engineer a 
functional implant one must understand the physiology of the trachea (Figure 1). 
 Figure 1: Anatomy of the human trachea. 
 
 
The trachea is a vascularised hollow tube that forms the airway passage between the larynx and the lungs. 
Structurally, it is composed of layers of connective tissue and smooth muscle, supported by U-shaped rings of 
hyaline cartilage that hold it open. Internally it is lined with pseudostratified columnar epithelium, with ciliated, 
brush, basal, and secretory cells on a basement membrane
10
. The trachea develops from the respiratory 
diverticulum. In the third to fourth week of life, the hepatic primordium migrates from the respiratory 
primordium, allowing the respiratory primordium to dilate and bifurcate ventrocaudally into lung buds. The 
lung buds give rise to the trachea, infra- glottis, and the glottic opening. By week 8, the mesenchymal rudiments 
of the tracheal cartilages are present. During the next 2 weeks, the cartilages develop into fibro-elastic tissue, 
and smooth muscle is incorporated into the trachea. 
 Figure 2: Development of the trachea. A. Lateral view at the end of week 3; B-C. Ventral view of development at week 4. 
 
The view is that the tissue engineered airway will replace the damaged organ, mimic the native extracellular 
matrix (ECM) in structure and function, while also providing support and encouraging cell attachment, 
differentiation, and proliferation
11
. This technique was originally pioneered by Langer and Vacanti 
12
 who 
showed that scaffold composition is a key feature, and can accelerate tissue regeneration even without cells or 
growth factors. Scaffolds may be biological, as a decellurised allotransplant, or composed of a synthetic 
material, which can be non-biodegradable or biodegradable. Synthetic scaffolds have been studied in various 
forms including polyethylene glycol-based hydrogel, polylactic/glycolic acid (PLGA), poly(e-caprolactone) 
(PCL), polyester-urethane, gelatin sponge, Marlex mesh and other modified forms (see table 1).  While many of 
these innovative treatments could potentially be utilised in adults, the treatment options for children are limited 
as the level of complexity increases due to variations in the size of the trachea, and changes over time due to 
growth. Here the focus is to review the application of decellularised scaffolds and synthetic and biodegradable 
polymers in tissue engineered airways, highlighting cellular interaction, and clinical applications.
  Species Scaffold Key Findings 
 
Wykoff et al 1973
5
 
 
Nude Mice (10) 
 
2 layers: 
1. Outer layer: PGA non-woven mesh 
seeded with shoulder-derived bovine 
chondrocytes 
2. Inner layer: silastic tube. 
  
 New cartilage formed after 4 weeks in 
vivo. 
  
 Both internal and external surfaces of the 
cylinders lined with vascularised 
connective tissue. 
  
 
Neville et al. 1990
6
 
 
New Zealand White Rabbits 
(17) 
 
3 layers: 
 External: copolymer (L-lactide/ε-
caprolactone) coarse mesh 
 Middle: PGA nonwoven mesh 
 Internal: collagen  
 Expanded chondrocytes seeded onto 
scaffold 24hrs pre-implantation. 
  
  
 Airway structure maintained up to 3 
months post implantation. 
  
 Epithelium regeneration occurred in the 
internal lining. 
  
 Cartilage accumulation observed in the 
tracheal wall. 
  
 No further follow-up data available. 
  
 
Shi et al. 2005
11
 
 
New Zealand White Rabbits 
(10) 
 
3 layers: 
 External surface: lateral thoracic facia 
 Cartilage substitute: polypropylene mesh 
 Inner surface: proximal ear epithelium. 
1.  
2. 3 deaths: 1 pre-anastomotic wound 
infection, 1 post-anastomotic lower 
respiratory tract infection,  
1 detachment of lower proximal 
anastomosis. 
 
 
 
Klin et al. 2007
13
 
 
Human (1: 30 year old female 
patient with end stage 
bronchomalacia) 
  
 DEM decellularisation of female human 
donor trachea. 
  
 Re-seeding with autologous epithelial and 
mesenchymal stem cells 
 Replacement of patient’s left main 
bronchus. 
  
  
 4 months: normal appearance and 
mechanical properties of graft. 
  
 Donor trachea particularly difficult to 
obtain for paediatric application. 
 
Jungebluth et al. 2011
9
 
 
Human (1: 36-year-old male 
patient with recurrent primary 
cancer of the distal trachea 
and main bronchi) 
1.  
2. POSS-PCU (polyhedral oligomeric 
silsesquioxane poly-[carbonate-urea] 
urethane nanocomposite) scaffold seeded 
with autologous bone-marrow mononuclear 
cells in a bioreactor for 36 hours prior to 
implantation. 
3.  
1.  
2. 5 months: patient asymptomatic and 
tumour-free. 
3.  
Partial coverage with nearly healthy 
vascularised mucosa and epithelium.  
Table 1: Cell seeded synthetic tracheal prostheses 
2. Scaffolds 
Tissue engineered scaffolds are designed to act as a supporting structure; maintain an open airway and mimic 
the biological and mechanical function of the native ECM; providing a template for the stem cells until they 
have proliferated, regenerated, and stabilised the damaged area
9
 (Figure 3).  
 
Figure 3: Schematic representation of the relationship between degradable scaffolds and tissue 
regeneration 
 
Most importantly it must be nontoxic, laterally rigid to prevent collapse, while also being flexible to 
accommodate the necks natural movements.  Flow of air into the trachea makes it prone to airborne infections 
such as bacterial and viral infections
13
. In native tissue, cilia provide a barrier and a mechanism for the 
expulsion of particulates. To mimic this action vascularization is needed at the air-tissue interface. A porous 
scaffold allows cell-polymer interactions for the ingrowth of host connective tissue
6,7
. It should also be 
biocompatible in terms of cell type, function, longevity, and immunogenicity. A scaffold that does not initiate a 
secondary immune response would eliminate the risk of implant rejection as well as the need for life-long 
immunosuppression, which is unsuitable in patients with cancers of the trachea. For degradable polymers the 
degradation products must be biologically safe. The scaffold also needs to degrade at an appropriate rate in 
relation to the regeneration of tissue to prevent structural collapse of the trachea. 
The type of scaffold is still an on-going debate but methods for tracheal replacement include the use of 
autologous tissue
14
 autografts
15
, allografts
7
 prosthetic materials
4,16,17
 or a combination of these approaches
1,18
. 
These works have met with limited success due to stenosis, immunological rejection, bacterial infections, graft 
migration and material failure
11
. Tissue engineered polymeric implants are preferable as they do not raise a 
substantial immune response, which can often be seen in allografts. Despite this TE tracheal transplants have 
already been carried out clinically in a few compassionate cases
7,13,19–21
. None of the current scaffold approaches 
have the potential to grow with the patient; therefore, sustainability is limited in growing children
3
. There are 
three areas of focus for scaffolds used in airway tissue engineering: allogenic decellurised tissue, and 
biodegradable, or non-biodegradable synthetic scaffolds. 
 
 
2.1 Decellularised Scaffolds 
Decellularised scaffolds are currently the most widely used TE tracheal implant in the clinical setting. To create 
a decellularised scaffold a donor trachea is harvested from a cadaver, subjected to numerous washing cycles to 
remove donor cells via detergents, salts, enzymes, and/or physical means
22,23
 and is then recellularised with the 
patient’s own cells. This gives a TE trachea good biomechanical properties, functional extracellular matrix 
(ECM), and removes the possibility of an immune response by eliminating major histocompatibility complexes 
class I and II
24
. For the scaffold to fully integrate it must have a healthy ECM composed of proteins, collagen 
subunits, proteoglycans and glycoproteins; all of which the decellularisation process retains, maintaining the 
tissues ability to develop and grow, and also removes immune responsiveness
25
. 
Decellularised tissue engineered tracheas have been investigated in a number of studies to date, with varied rates 
of success
8,25–27
. While good epithelialisation was observed in many, the grafts were structurally unstable 
leading to airway obstruction and subsequent collapse. The first in human tissue-engineered tracheal 
replacement was performed in 2008, on a 30-year old female patient with end-stage bronchomalacia
13
. A donor 
trachea was decellurised via the detergent-enzymatic method
22
 and seeded with epithelial cells and 
mesenchymal stem cell-derived chondrocytes from the recipient. The graft was structurally sound with good 
rates of revascularisation, epithelialsation and no immunological response or serological signs of rejection. On 
follow-up 5 years later the tissue-engineered trachea itself was patent, well vascularised, completely 
recellularised with respiratory epithelium, and had normal ciliary function and mucus clearance
28
. However, 
patency of the lumen was suboptimal with the graft requiring dilatation and stenting intermittently. 
Since this case, there have been several other clinical cases performed worldwide but very few involved children 
receiving a tissue engineered tracheal transplant. One case in 2012 saw the use of a decellularised donor trachea, 
implanted into a 10-year-old boy to repair a 7cm section of damaged trachea, due to long-segment congenital 
tracheal stenosis and pulmonary sling. No seeding with epithelial cells, mesenchymal stem cells (MSC), or 
chondrocyte differentiation occurred before the surgery due to the immediacy of the procedure. Instead an 
intraoperative procedure was used; prior to implantation the donor trachea was saturated with a cell suspension 
of haematopoietic and MSCs and also human recombinant erythropoietin. Granulocyte-colony stimulating 
factor (G-CSF) and transforming growth factor beta (TGF-B) were injected to the tracheal rings to aid MSC 
proliferation and recruitment, chondrocyte differentiation, and angiogenesis. Temporary stenting was required 
following surgery, while bronchoscopy and balloon dilation were carried out regularly to clear mucus build-up. 
Nevertheless, the clinical course was good. At 6 months post-op, the airway was patent and stable, balloon 
dilation was still needed, but at 18 months post-surgery the child was healthy and fit with no signs of 
complication
19
.  
Additionally, a case series of nine adult and paediatric patients were reported in a review by Badylak et al.
29
 in 
2012 which stated that there were no graft related mortalities 12-42 months following surgery, however partial 
graft collapse had occurred in some instances. Unfortunately, these cases have not yet been reported or followed 
up in a formal scientific paper, making it difficult to surmise the outcomes. While decellularised donor implants 
have been successful in certain compassionate cases, the method has not been optimised or clinically trialed yet. 
In the future if a standard framework for this procedure can be identified and tested it is possible these could be 
used clinically, but will still be limited by the shortage of donor tissue. 
 
2.2 Synthetic Scaffolds 
In tissue engineering, one of the most debated issues is the choice of synthetic scaffold. There are numerous 
options for a synthetic scaffold as previously mentioned, but these are generally composed of modified 
polymers, often in combination with biological elements. Studies have shown that inserting chondrocytes for 
cartilage growth in natural materials like gels or sponges, including alginate, collagen and agarose, can help to 
promote collagen type II and proteoglycan synthesis
16
. Omori et al
30
 developed a collagen-conjugated prosthesis 
for tracheal replacement composed of polypropylene Marlex mesh, a spiral ring frame, and collagenous sponge 
extracted from porcine skin. This scaffold was applied to repair the larynx and trachea in 4 adult patients. Post-
operative results were positive, and even though epithelialisation on the luminal surface took some time to 
develop, follow-up studies reported good epithelisation and no signs of graft rejection after three years.  
A novel synthetic nanocomposite polymer reseeded with autologous mononuclear cells was used to create the 
worlds’ first completely synthetic tracheal transplant in 201131. The POSS–PCU nanocomposite material is 
composed of a polycarbonate (urea) urethane soft segment (PCU) and a polyhedral oligomeric silsequioxane 
(POSS) cage attached as a pendant group. This non-biodegradable material is biocompatible, nontoxic, and 
elicits a low inflammatory response in vivo
32
. The recipient, a 36 year-old male, suffered from recurrent primary 
cancer of the distal trachea and main bronchi. As resection was unsuitable in this case, a novel bioartificial 
nanocomposite was designed to replace the section of trachea affected. The initial surgical outcome was 
encouraging, however biopsy samples showed the presence of necrotic connective tissue due to fungal infection. 
Nevertheless, 5 months after transplantation the patient was asymptomatic, did not show signs of rejection, had 
a patent airway and the mucosa was vascularized with a near-normal epithelium.  
While these materials provide researchers with a highly modifiable graft that can be customised according to the 
requirements of the patient, there are still major associated risks. The synthetic materials can be poorly 
incorporated by native tissues; resulting in complications such as graft migration, stenosis, infection and the 
formation of granulation tissue at the anastomosis site. 
 
2.3 Biodegradable Synthetic Scaffolds 
For paediatric applications, the choice of scaffold is a key consideration. Tracheal defects affecting children 
include congenital and pediatric lesions, tracheal stenosis, tracheoesophageal fistulae, complete tracheal rings, 
tracheomalacia, laryngotracheoesophageal cleft, and damage due to prolonged intubation and tracheal trauma
33
. 
The treatment options available to children are even more limited in comparison to adults as the maximum 
resectable length of the trachea is limited to 30% due to the amount of tissue available. Thus, there is currently 
no viable tracheal replacement for children. For paediatrics, the use of a biodegradable scaffold that replaces the 
damaged tracheal section and supports tissue modification, cellular migration and proliferation, while also 
degrading at a suitable rate during growth would be highly desirable, as it would eliminate the need for recurrent 
surgeries. Polymers can degrade in two distinct ways; via surface or bulk degradation. In surface degradation the 
material is eroded layer by layer, reducing in thickness whilst maintaining the original shape, however in bulk 
degradation the polymer is lost through disintegration, weakening the device at unspecified points across the 
surface of the scaffold. This distinction is important when thinking about the structural integrity of the implant, 
because if it degrades at a rate that is too rapid, there is an increased risk of luminal collapse. As the polymer 
erodes, the cells must also be able to withstand the changeable environment. Equally, the degradation products 
must not be toxic, or initiate an immune response. The rate of degradation is malleable as it is dependent on the 
type of chemical bonds in the material, pH of the environment, polymer composition, and water uptake
34
.  
Synthetic scaffolds hold much promise for future directions but problems such as poor biocompatibility, graft 
migration, and insufficient integration with the native tissue, remain unresolved. Furthermore, biodegradable 
scaffolds also have unique complications to overcome, like the release of harmful degradation products and loss 
of mechanical properties over time. The majority of biodegradable polymers being studied for clinical 
application are from the polyester family. These are based on lactic and glycolic acids that degrade in vivo via 
hydrolysis of the ester backbone, producing clean by-products that can be easily excreted by the body. 
Poly(glycolic acid) (PGA), poly (lactic acid) (PLA), Poly(caprolactone) (PCL) and their copolymers are the 
most widely used biodegradable polymers in tissue engineering 
35
. 
 
 
3. Biodegradable Tissue Engineered Airways 
Poly(glycolic acid) (PGA) has excellent properties for use in tissue engineering. Its degradation product, 
glycolic acid, is converted to carbon dioxide and water; these can then be excreted through the lungs or kidneys, 
making it non-toxic and non-immunogenic. As a material, PGA serves as a conducive environment for cell 
growth, its degradation rate can be adapted, and porosity modified to encourage ECM formation and 
vascularisation through cell-polymer interactions
36
. Since the 1970s, the main use of PGA has been to produce 
resorbable sutures, but it is now being used in mesh-form for tissue engineering purposes
35
.  
Polylactic acid (PLA) is commonly used in scaffolds, drug delivery systems, bone fixation devices such as 
screws and plates, surgical sutures, and meshes. PLA’s degradation product is lactic acid, which naturally occurs 
in the body. Due to the similarities between PLA and PGA, scaffolds are often formed from a copolymer of 
these. Since PLA is more hydrophobic than PGA, this changes the rate of degradation and mechanical stability 
of the scaffold as the ester bonds in PLA are more resistant to hydrolysis
35
. When degrading, PLA and PGA can 
produce high concentrations of lactic and glycolic acids, these can negatively impact on the local environment 
due to the acidic content. 
With a degradation time between two to three years, Poly(caprolactone) (PCL) is useful as a base polymer for 
long-term biodegradable implants, as it degrades at a slower rate than PLA or PGA
37
. Polyurethanes were once 
unsuitable for use in vivo due to the toxicity of their degradation product (2,4- diaminotoluene). Since then, 
biodegradable polymers have been modified such that degradation products are now non-toxic
38
. The 
incorporation of polyhedral oligomeric silsesquioxane (POSS) into poly (Ɛ-caprolactone) (PCL) has improved 
the polymers mechanical properties further, preventing the ester bonds in PCL from degrading through 
enzymatic attack to the same extent. The properties of these nanocomposite materials lend themselves to the 
development of a multitude of scaffolds and organs. Biodegradable polymers have been used to create vascular 
grafts
39
, resorbable sutures, drug delivery systems, orthopaedic fixtures
35
, artificial skin, even bone substitutes
40
. 
One of the most applicable uses for biodegradable polymers has been to create resorbable stents. Stents are 
currently manufactured from non-resorbable materials, like plastic and metal. These lead to patient discomfort, 
and significant clinical complications such as migration, haemorrhage, infection, stenosis, and tissue 
granulation. Biodegradable stents have already been developed for oesophageal, intestinal, urethral, biliary duct, 
vascular stenosis and more recently for airway stenosis, therefore could be modified to produce larger constructs 
like tracheal scaffolds
41
. 
 
In paediatric cases the use of biodegradable scaffolds, rather than an allotransplant, is also preferable for 
tracheal replacement, which becomes obvious when the following factors are considered. The use of tracheal 
allotransplants has had a certain amount of success clinically for both adults and children, but the sustainability 
of such implants is limited. The availability of donor tissue is a rate-limiting step in the process, one that also 
requires the tissue to be compatible in terms of size and suitability. The long-term outcomes from the use of 
decellurised donor scaffolds are not known yet, and it remains to be seen if the detergent-enzymatic method 
(DEM) removes all potential immune responses, or if the stringent chemical processes raise any complications 
in vivo. DEM is not a quick process; to fully remove the MHC antigens class I and II along with the DNA and 
leukocytes requires 25 washing cycles. Donor scaffolds are not available on demand and the time taken to 
prepare a scaffold, even when expedited, requires 5 weeks
42
. For use in paediatric cases finding a size match 
adds another level of complexity. A biodegradable scaffold would provide an alternative, sustainable option, 
which can degrade as the child grows and the native tissue regenerates. If the scaffold could be optimised it 
could mean being able to repair a defect in one procedure, a feature allotransplants cannot currently offer. 
 
4. Cell Interactions 
4.1 Cell Selection 
Two cell types essential for the success of a synthetic trachea are epithelial cells to line the airway, and 
chondrocytes to form new tracheal cartilage. Cell populations that make up this ciliated pseudostratified 
columnar epithelium include ciliated, goblet, and basal cells. As the trachea is exposed to the external 
environment through the passage of air, respiratory epithelium provides essential protection and maintains 
homeostasis. This cell network produces mucosal layers to trap particulates and pathogens, clear mucus, 
maintain the water/ion balance, and sustain a healthy epithelium throughout the repair and regeneration process.  
Chondrocytes produce and conserve the extracellular matrix of cartilage. The main sources for chondrocytes are 
auricular, nasal, tracheal, and costal cartilage. The U-shaped rings of the trachea are formed from hyaline 
cartilage, which is only present in the joints, the respiratory tract, and the immature skeleton. The distinction 
between the types of cartilage (hyaline, elastic and fibrocartilage) can be problematic when sourcing and 
culturing chondrocytes for a specific purpose. Chondrocytes have proven more difficult to harvest and grow 
than epithelial cells. To address this issue, bone marrow mesenchymal stem cells (MSCs) can be employed and 
subsequently differentiated into chondrocytes as well as epithelial cells. Over time, chondrocytes cultured in 
vitro, irrespective of their source, change their gene expression and effectively dediffrentiate. To account for this 
behaviour, chondrocytes are often seeded onto or within gels like agarose or collagen, as the three dimensional 
environment appears to better support their differentiation into hyaline cartilage
3,24,43
. 
Cell sources available for use in tissue engineering include induced pluripotent stem cells, adult stem and 
progenitor cells, and lineage-committed and differentiated adult tissue cells. Cell choice is dependent on 
availability, expansion capacity, accessibility, and its potential for tumorgenicity through differentiation.  
Embryonic stem cells are the undifferentiated inner mass cells of a human embryo. As the earliest pluripotent 
stem cells, they have the potential to differentiate into multiple lineages. Alternatively, cells can be sourced from 
foetal, umbilical cord, or placental tissue. These cell populations also have a high expansion capacity but the cell 
fates are already somewhat defined and long-term they have the tendency to become cancerous. While they have 
unrivaled potential, there are tight ethical regulations surrounding the use of embryonic or foetal stem cells 
making them unsuitable for regular use in the seeding of tracheal scaffolds.  
Induced pluripotent stem cells (iPSCs) generated from adult cell populations are an attractive alternative to 
embryonic or foetal stem cells. These iPSCs exhibit the same morphology, expansion and differentiation 
properties, and also express the same cell marker genes as embryonic stem cells. Adult somatic cells are 
essentially reset to progenitor cells, driven by a series of transcription factors
44
.  However, this technique is yet 
to be refined as iPSCs have failed to fully commit to their reprogrammed cell lineage and have a tendency for 
tumorgenicity.  Techniques are still improving for creating iPSCs and there is great potential for them to be a 
valuable source of stem cells in the future. 
Adult stem cells comprise somatic cells with the ability to self renew. These can be derived from many adult 
tissues including adipose tissue, bone marrow, and peripheral blood. The use of an autologous stem cell 
population is a more viable choice when repopulating any tracheal implant, as immune matching reduces the 
probability of graft failure and rejection. However, harvesting these cells from the patient may prove difficult as 
this can be quite an invasive procedure. Though some adult stem cells have failed to proliferate fully when 
trialed in animal models, bone marrow mesenchymal stem cells are used regularly in clinical applications, 
including for tracheal scaffold reseeding. Autologous MSCs are easily accessible from the bone marrow, have 
no potential for immunogenicity, have a much lower incidence of tumorgenicity, and expansion rates are 
favourable. MSCs have the ability to differentiate into various cell types in vitro and are also involved in tissue 
repair. This makes them an excellent candidate for tissue engineered airways, as MSCs have been shown to 
differentiate into endothelial lineages
23
. 
Fibroblasts synthesise the extracellular matrix and collagen network that forms the basic structure for all tissues.  
They play a key role in epithelial-mesenchymal cell interactions and have been shown to support epithelial and 
mesenchymal cell growth through the reconstruction of the basement membrane
45
. Fibroblasts also improve cell 
migration, proliferation, and differentiation into ciliated, goblet and basal cells, allowing for the reconstruction 
of a pseudostratified ciliated epithelium similar to a native epithelium.
45
 They’ve also been shown to increase 
the rate of epithelial cell growth, although the source of fibroblasts is a determining factor; gingival fibroblasts 
were indicated to be better than nasal and dermal fibroblasts
45,46
. The range of cells applicable to airway tissue 
engineering suggests that the development of a seeded constructs is a viable option, therefore this is a promising 
experimental approach. 
 
 
7. Experimental approach 
In addition to decellularised and seeded scaffolds, 3D printing and bioprinting have become highly adaptable 
techniques for creating bespoke tissue engineered scaffolds. This technique permits the production of 3D solid 
scaffolds of any shape from digital images i.e. CT scans, giving a high level of reproducibility and control over 
the material properties of the scaffold, such as porosity and surface roughness. Advancements have been made 
with the development of bioprinting; allowing for both the printing of a support structure on which the cells can 
proliferate, and the incorporation of cell populations and biological cues into the ink, resulting in a completely 
cohesive scaffold.  
The methods for 3D printing vary; they include inkjet, laser-induced forward transfer, microextrusion or 
stereolithography and projection pattern formats
47
. Each method comes with its own pros and cons, such as 
mechanical stress, cost, clogging, or limited material use. One of the main benefits in 3D printing scaffolds is 
the accuracy and reproducibility compared to traditional procedures, so material printability and printer method 
must be carefully considered. However, a key notation is that despite the advantages, the issue of selecting a 
suitable printing material to mimic the native tissue remains. Natural materials have an inferior structural 
integrity in comparison to the synthetic materials, but do provide a superior biocompatible environment. The 
opposite can be said for synthetic polymers, which show higher mechanical strength, but have a limited degree 
of biocompatibility. For this reason the combination of natural and synthetic materials into a hybrid scaffold 
would result in a prosthesis which satisfies the desired parameters.  
The choice of cells is dependent on the target application; in this case epithelial cells and mesenchymal cells to 
generate airway epithelium and cartilage. However, another selection factor to consider is the robustness of the 
cells as they have to withstand stresses from the bioprinting process. Encapsulating cells in hydrogels creates a 
tissue-like environment increasing viability, which is often is often affected in bioprinting. A 3D printed PCL 
scaffold coated with mesenchymal stem cells seeded in fibrin was tested for the repair of partial tracheal defects 
in vivo
48
. The 3D printed scaffold integrated well with the native tissue. The reconstructed trachea was 
successfully covered with regenerated respiratory epithelium, neo-cartilage formed and minimal granulation 
tissue was seen at suture points.  
The potential of bioprinting is undeniable; however as a relatively new approach for the development of tissue 
engineered scaffolds, refinements are needed in printing methods, ink compositions and scaffold properties. 
 
8. Conclusion 
After decades of research, there now appear to be promising avenues to explore in order to successfully tissue 
engineer the airway.  As highlighted in this article, published research suggests that a promising approach may 
be to decellularise a cadaveric trachea and recellularise it with the patient’s own cells24. This option has been 
applied clinically, with successful outcomes recorded from patient reports
13,19
. However, most published follow-
up papers report weak mechanical properties, at least for the initial months post-implantation, with most cases 
requiring stenting to maintain patency
19,28,29
. Another issue with this approach is that it is not time efficient as 
the duration required find a donor and decellularise the scaffold may be problematic, specifically for cancer and 
trauma patients where a rapid replacement may be required. Additionally, a standard decellularisation protocol 
must be vigorously validated to prepare for potential variance between donor tissues. Turning to synthetic 
scaffolds appears to offer some theoretical advantages over scaffolds of biologic origin. These include the lack 
of an allorejection response rendering immunosuppressive therapy unnecessary, the potential to be tailor-made 
and/or 3D printed to each individual patient’s specific requirements and dimensions and a high degree of 
malleability allowing for good control of the strength, microstructure, degradation rate and porosity of the 
scaffold. These scaffolds may be ‘off the shelf’ accessible for urgent cases, without waiting for donor tissue. 
High-throughput production can also be tightly regulated and the constructs sterilised with ease. The 
disadvantages of this approach, on the other hand, include mechanical mismatch and poor integration resulting 
in formation of granulation tissue at the anastomosis sites.  With advances in 3D bioprinting technology, the 
combination of synthetic materials and printable biological components appears to be feasible and the most 
rational approach to achieving success in airway tissue engineering within the next decade.  
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